Information Provided By:
Fly News Breaks for February 25, 2020
Feb 25, 2020 | 07:47 EDT
Cowen analyst Ryan Blicker raised his price target to $90 from $85 following Q4 results. The analyst noted guidance was above consensus and he continues to view the near-term setup as attractive with room for upside. He said more importantly, the company is positioned for another strong year driven by Control-IQ with clear potential paths to significant revenue upside. Blicker reiterated his Outperform rating on Tandem Diabetes shares.